Tirzepatide, commonly known as Mounjaro, is a weekly injection shown to help weight loss and improve related health conditions.

As of 23 June 2025, a small number of GP practices in West Yorkshire started to contact people who might be medically eligible for this treatment to invite them for a clinical assessment.

Mounjaro is being introduced in a small number of GP practices as part of wider support for people living with obesity. There is no need to contact your GP practice - eligible patients will be contacted directly by their practice or the NHS.

This treatment is only available to a limited number of patients in the first year, based on strict NHS criteria. To qualify for this treatment patients must have the following -

• BMI of 40 and above

and four of the following serious weight-related health conditions

• hypertension
• Type 2 Diabetes
• Cardiovascular disease
• obstructive sleep apnoea
• dyslipidaemia

Patients have to agree to take part in a structured support programme including healthy eating and physical activity.